Subtopic Deep Dive

← Phosphodiesterase function and regulation

PDE Regulation by G Protein-Coupled Receptors
Research Guide

What is PDE Regulation by G Protein-Coupled Receptors?

PDE regulation by G protein-coupled receptors involves GPCR-mediated activation, recruitment, and phosphorylation of phosphodiesterases to control cAMP/cGMP signaling in feedback loops and compartmentalization.

GPCRs regulate PDEs through PKA phosphorylation, β-arrestin scaffolding, and dynamic compartmentalization, shaping signal transduction duration and specificity (Houslay and Adams, 2003; 756 citations). Key studies highlight PDE4 recruitment to mAKAP scaffolds by GPCRs and PDE5 inhibition in nitric oxide pathways (Dodge, 2001; Corbin and Francis, 1999). Over 10 papers from the list address GPCR-PDE crosstalk in desensitization and drug response.

Curated Papers

Key Challenges

Why It Matters

GPCR-PDE regulation controls receptor desensitization, critical for GPCR drug efficacy in heart failure and antidepressants (Houslay and Adams, 2003; Shah et al., 2016). PDE4 orchestration of cAMP cross-talk impacts hippocampal CREB expression in chronic antidepressant treatment (Nibuya et al., 1996; 1198 citations). PDE5 targeting by sildenafil demonstrates therapeutic potential in erectile dysfunction via cGMP modulation (Corbin and Francis, 1999). This axis influences HFpEF phenotype-specific treatments (Shah et al., 2016; 933 citations).

Key Research Challenges

Mapping GPCR-PDE scaffolds

Identifying precise phosphorylation sites and β-arrestin roles in PDE recruitment remains unresolved due to compartmentalization complexity (Houslay and Adams, 2003). Dynamic modeling of mAKAP-PDE4-PKA modules requires advanced imaging (Dodge, 2001). Few studies quantify feedback loop kinetics in live cells.

Quantifying signaling cross-talk

Distinguishing PDE4-specific cAMP hydrolysis from global pools challenges isoform selectivity (Houslay and Adams, 2003). GPCR desensitization metrics vary by cell type, complicating therapeutic translation (Francis et al., 2010). Kinetic assays show isoform-specific regulation gaps.

Translating to drug efficacy

HFpEF trials reveal phenotype-specific GPCR-PDE failures despite PDE5 inhibitors (Shah et al., 2016). Chronic antidepressant CREB induction via PDE lacks GPCR specificity (Nibuya et al., 1996). Clinical models underexplore compartmental effects.

Essential Papers

Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus

Masashi Nibuya, EJ Nestler, R. S. Duman · 1996 · Journal of Neuroscience · 1.2K citations

The present study demonstrates that chronic, but not acute, adminstration of several different classes of antidepressants, including serotonin- and norepinephrine-selective reuptake inhibitors, inc...

cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action

Sharron H. Francis, Jennifer L. Busch, Jackie D. Corbin · 2010 · Pharmacological Reviews · 988 citations

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction

Sanjiv J. Shah, Dalane W. Kitzman, Barry A. Borlaug et al. · 2016 · Circulation · 933 citations

Heart failure (HF) with preserved ejection fraction (EF; HFpEF) accounts for 50% of HF cases, and its prevalence relative to HF with reduced EF continues to rise. In contrast to HF with reduced EF,...

PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization

Miles D. Houslay, David R. Adams · 2003 · Biochemical Journal · 756 citations

cAMP is a second messenger that controls many key cellular functions. The only way to inactivate cAMP is to degrade it through the action of cAMP phosphodiesterases (PDEs). PDEs are thus poised to ...

Cyclic GMP Phosphodiesterase-5: Target of Sildenafil

Jackie D. Corbin, Sharron H. Francis · 1999 · Journal of Biological Chemistry · 534 citations

The advent of the medication, sildenafil, 1Tradename VIAGRA™. 1Tradename VIAGRA™. for treatment of male impotence has attracted widespread attention. This agent potently inhibits a cGMP-binding cGM...

The Cyclic AMP Pathway

Paolo Sassone‐Corsi · 2012 · Cold Spring Harbor Perspectives in Biology · 512 citations

cAMP was the first second messenger to be identified. Its three main effectors are PKA (which phosphorylates numerous metabolic enzymes), EPAC (a guanine-nucleotide-exchange factor), and cyclic-nuc...

mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module

Kimberly L. Dodge · 2001 · The EMBO Journal · 500 citations

Reading Guide

Foundational Papers

Start with Houslay and Adams (2003; 756 citations) for PDE4 cross-talk overview, then Dodge (2001; 500 citations) for mAKAP-GPCR modules, and Nibuya et al. (1996; 1198 citations) for cAMP-CREB in antidepressants.

Recent Advances

Shah et al. (2016; 933 citations) on HFpEF GPCR-PDE phenotypes; Sassone-Corsi (2012; 512 citations) on cAMP pathways; Francis et al. (2010; 988 citations) on cGMP action.

Core Methods

PDE activity assays post-GPCR agonist; phospho-site mapping by mass spec; compartmental modeling with scaffolds like mAKAP; FRET for cAMP/cGMP dynamics (Houslay and Adams, 2003; Dodge, 2001).

How PapersFlow Helps You Research PDE Regulation by G Protein-Coupled Receptors

Discover & Search

Research Agent uses searchPapers and citationGraph to map GPCR-PDE papers from Houslay and Adams (2003), revealing 756 citing works on desensitization, then findSimilarPapers uncovers Dodge (2001) mAKAP scaffolds. exaSearch queries 'GPCR PDE4 phosphorylation sites' for 250M+ OpenAlex integration.

Analyze & Verify

Analysis Agent applies readPaperContent to extract PDE4 modular domains from Houslay and Adams (2003), verifies claims with CoVe chain-of-verification, and runs PythonAnalysis on cAMP kinetic data for GRADE evidence grading of phosphorylation rates. Statistical verification confirms PKA-PDE4 feedback in Dodge (2001).

Synthesize & Write

Synthesis Agent detects gaps in GPCR-PDE modeling from Francis et al. (2010), flags contradictions in cGMP cross-talk, and uses exportMermaid for signaling loop diagrams. Writing Agent employs latexEditText, latexSyncCitations for Corbin and Francis (1999), and latexCompile for publication-ready reviews.

Use Cases

"Model PDE4 activation kinetics by beta-adrenergic GPCR using Python."

Research Agent → searchPapers 'PDE4 GPCR kinetics' → Analysis Agent → readPaperContent (Houslay 2003) → runPythonAnalysis (NumPy ODE solver on cAMP hydrolysis) → matplotlib plot of feedback loop dynamics.

"Compile review on GPCR-PDE desensitization with citations."

Research Agent → citationGraph (Nibuya 1996) → Synthesis → gap detection → Writing Agent → latexEditText (add sections) → latexSyncCitations (10 papers) → latexCompile → PDF with GPCR feedback diagrams.

"Find code for simulating mAKAP-PDE4 scaffolds."

Research Agent → searchPapers 'mAKAP PDE4 simulation' → Code Discovery → paperExtractUrls (Dodge 2001 cites) → paperFindGithubRepo → githubRepoInspect → exportCsv of simulation parameters.

Automated Workflows

Deep Research workflow scans 50+ GPCR-PDE papers via searchPapers → citationGraph → structured report on desensitization (Houslay 2003). DeepScan applies 7-step analysis: readPaperContent (Francis 2010) → CoVe verify → runPythonAnalysis on cGMP kinetics → GRADE report. Theorizer generates hypotheses on PDE5-GPCR loops from Corbin (1999) data.

Try Doxa for PDE Regulation by G Protein-Coupled Receptors Research

Frequently Asked Questions

What defines PDE regulation by GPCRs?

GPCRs regulate PDEs via PKA phosphorylation, β-arrestin recruitment, and scaffold assembly to hydrolyze cAMP/cGMP, enabling desensitization and cross-talk (Houslay and Adams, 2003).

What methods study GPCR-PDE interactions?

Kinetic assays measure PDE activation post-GPCR stimulation; FRET imaging tracks compartmentalization; phosphorylation mutants dissect sites (Dodge, 2001; Houslay and Adams, 2003).

What are key papers on this topic?

Houslay and Adams (2003; 756 citations) on PDE4 signaling; Dodge (2001; 500 citations) on mAKAP scaffolds; Francis et al. (2010; 988 citations) on cGMP PDEs.

What open problems exist?

Quantifying isoform-specific kinetics in vivo; modeling β-arrestin-PDE scaffolds dynamically; translating compartmental effects to GPCR drug design (Shah et al., 2016).